Navigation Links
AstraZeneca Completes Enrollment in Two Pivotal Phase III Studies of the Investigational Drug Vandetanib (ZACTIMA(R)) in Non-Small Cell Lung Cancer (NSCLC)

WILMINGTON, Del., March 12 /PRNewswire-FirstCall/ -- AstraZeneca (NYSE: AZN) announced today that it has completed patient enrollment in two pivotal Phase III studies for vandetanib, the company's investigational, once-daily oral anti-cancer drug, for the second-line treatment of non-small cell lung cancer (NSCLC). The two studies -- ZODIAC (ZACTIMA in cOmbination with Docetaxel In non-smAll cell lung Cancer) and ZEAL (ZACTIMA Efficacy with Alimta in Lung cancer) -- are the second and third of four ongoing studies to complete enrollment. Data from the studies are expected later this year and the broad development program is on track for a first regulatory submission in 2008.

ZODIAC is a randomized, double-blind, international, multi-center Phase III study to assess the efficacy of vandetanib 100mg once-daily plus the standard docetaxel chemotherapy versus docetaxel alone in 1,380 patients with locally advanced or metastatic NSCLC after failure of first-line anti-cancer therapy.

ZEAL is a Phase III parallel group, randomized, double-blind study evaluating vandetanib 100mg once daily plus pemetrexed 500mg/m2 (every 3 weeks) compared with placebo plus pemetrexed as second-line treatment in 510 patients with locally advanced or metastatic NSCLC who have failed first-line anti-cancer therapy.

The ZEST study, which is investigating vandetanib versus erlotinib, was the first Phase III study of vandetanib to complete enrollment in November 2007.

"NSCLC is an area of high unmet medical need, and we hope vandetanib will offer a beneficial new treatment option that may improve the lives of people with lung cancer," said Dr. Peter Langmuir, Medical Science Director at AstraZeneca.

ZODIAC and ZEAL are part of a broad Phase III clinical trial program designed to gain an understanding of how vandetanib may benefit people with lung cancer.
The other studies are:

-- ZEST (vandetanib versus erlotinib) enrollment is complete; and

-- ZEPHYR (vandetanib + best supportive care (BSC) versus BSC).

The ZEPHYR study is currently recruiting patients.

The Phase III program in NSCLC follows results from two Phase II trials where vandetanib was studied either alone or in combination with standard chemotherapy (docetaxel).(1)(2) Vandetanib is also being evaluated as a treatment option in medullary thyroid cancer and has been awarded Food and Drug Administration (FDA) orphan drug status and fast track designation for this tumor type.

About vandetanib (ZACTIMA(R))

Vandetanib is an investigational compound being studied as a once-daily oral therapy that fights cancer through two clinically important mechanisms: inhibiting vascular endothelial growth factor receptor 2 (VEGFR2), which blocks the development of tumor blood supply; and inhibiting the epidermal growth factor receptor (EGFR), which may lead to direct inhibition of cancer cell growth and survival.(3)(4) Vandetanib also inhibits RET kinase activity which may be important to the growth and development of certain tumors.(5)

Vandetanib is currently being investigated alone and in combination with chemotherapy treatments to determine its impact in treating a number of solid tumors.

About AstraZeneca

AstraZeneca is a major international healthcare business engaged in the research, development, manufacturing and marketing of meaningful prescription medicines and supplier for healthcare services. AstraZeneca is one of the world's leading pharmaceutical companies with healthcare sales of $29.55 billion and is a leader in gastrointestinal, cardiovascular, neuroscience, respiratory, oncology and infectious disease medicines. In the United States, AstraZeneca is a $13.35 billion dollar healthcare business with 12,200 employees committed to improving people's lives. AstraZeneca is listed in the Dow Jones Sustainability Index (Global) as well as the FTSE4Good Index. For more information visit .

ZACTIMA is a registered trademark of the AstraZeneca group of companies.

(1) Natale RB et al. ZD6474 versus gefitinib in patients with advanced

NSCLC: Final results from two-part, double-blind randomized phase II

trial. Journal of Clinical Oncology, Vol 24, No 18S, 2006: 7000.

(2) Heymach JV et al. Randomized, Placebo-Controlled Phase II Study of

Vandetanib Plus Docetaxel in Previously Treated Non-Small-Cell Lung

Cancer. Journal of Clinical Oncology 2007, Vol 25, No 27, 2007:


(3) Wedge, S.R et al. ZD6474 inhibits vascular endothelial growth factor

signaling, angiogenesis, and tumor growth following oral

administration. Cancer Res 2002; 62(16):4645-55.

(4) Holden SN, Eckhardt SG, Basser R et al. Clinical evaluation of ZD6474,

an orally active inhibitor of VEGF and EGF receptor signaling, in

patients with solid, malignant tumors. Ann Oncol 2005; 16(8):


(5) Tada, H, Vasselli, J, Langmuir, P. Clinical Potential of Vandetanib,

an Oral Inhibitor of Key Tumor Signaling Pathways. Proceedings of the

10th International Symposium on Anti-Angiogenesis Agents. Feb. 7-9,


SOURCE AstraZeneca
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. AstraZeneca Submits sNDA for SEROQUEL XR(TM) for the Treatment of Major Depressive Disorder
2. AstraZeneca Response to February 21, 2008 Ruling In Re: Alabama Medicaid Pharmaceutical AWP Litigation - cv2005-219 - Circuit Court of Montgomery, Alabama
3. Meditrina Pharmaceuticals, Inc. Announces Exclusive Global License Agreement With AstraZeneca
4. Epistem plc and AstraZeneca Complete Plucked Hair Biomarker Study for Oncology Drug Development
5. AstraZeneca and Banner Alzheimers Institute Collaborate to Evaluate New Tool Targeting Alzheimers Disease
6. AstraZeneca Bolsters Its Worldwide Biologics Division Through Integration of Cambridge Antibody Technology Into MedImmune
7. Pediatric Asthma Programs Featuring PARI Pharmas eFlow Acquired by AstraZeneca
8. BrainCells Inc. Completes $30 Million Initial Closing of Series B Financing
9. PharmAthene Completes Pharmacokinetic Studies of Protexia(R); Program on Target for IND Filing in 2008
10. D-Pharm Completes Pre-IND Meeting With the FDA for Treatment of Acute Stroke With DP-b99
11. Plurality Completes R&D of its HAL-256 Multicore Processor
Post Your Comments:
(Date:11/25/2015)... San Francisco, CA (PRWEB) , ... November 25, ... ... leading microbial genomics company uBiome, were featured on AngelList early in their initial ... by launching an AngelList syndicate for individuals looking to make early stage investments ...
(Date:11/24/2015)... 2015 Cepheid (NASDAQ: CPHD ) today ... following conference, and invited investors to participate via webcast. ...      Tuesday, December 1, 2015 at 11.00 a.m. Eastern Time ...      Tuesday, December 1, 2015 at 11.00 a.m. Eastern Time ... New York, NY      Tuesday, December 1, 2015 ...
(Date:11/24/2015)... ... November 24, 2015 , ... Copper is an essential ... bound to proteins, copper is also toxic to cells. With a $1.3 million ... (WPI) will conduct a systematic study of copper in the bacteria Pseudomonas aeruginosa ...
(Date:11/24/2015)... , Nov. 24, 2015  Clintrax Global, Inc., a worldwide ... Carolina , today announced that the company has set a ... a 391% quarter on quarter growth posted for Q3 of 2014 ... and Mexico , with the establishment of ... December 2015. --> United Kingdom and ...
Breaking Biology Technology:
(Date:11/9/2015)... SAN JOSE, Calif. , Nov. 9, 2015 /PRNewswire/ ... of human interface solutions, today announced broader entry into ... of vehicle-specific solutions that match the pace of consumer ... drivers, and biometric sensors are ideal for the automotive ... the vehicle. Europe , ...
(Date:10/29/2015)... 29, 2015   MedNet Solutions , an innovative ... of clinical research, is pleased to announce that it ... (MHTA) as one of only three finalists for a ... Small and Growing" category. The Tekne Awards honor ... superior technology innovation and leadership. iMedNet™ ...
(Date:10/29/2015)... ANN ARBOR, Mich. , Oct. 29, 2015 ... with Eurofins Genomics for U.S. distribution of its ... DNA-seq kit and Rubicon,s new ThruPLEX Plasma-seq ... DNA to enable the preparation of NGS libraries ... in plasma for diagnostic and prognostic applications in ...
Breaking Biology News(10 mins):